MindMed has announced a partnership with MindShift Compounds AG, a Swiss drug discovery startup, to develop and patent next-gen psychedelic and empathogenic compounds. MindShift has already synthesized an initial tranche of such compounds, and the related patent applications have been filed by MindMed. MindMed hopes to begin Phase 1 clinical trials in relation to these compounds by Q1 2022…


Previous articleTryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor
Next articleMindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds